MX2021008962A - Metodo para tratar signos y sintomas de la osteoartritis. - Google Patents

Metodo para tratar signos y sintomas de la osteoartritis.

Info

Publication number
MX2021008962A
MX2021008962A MX2021008962A MX2021008962A MX2021008962A MX 2021008962 A MX2021008962 A MX 2021008962A MX 2021008962 A MX2021008962 A MX 2021008962A MX 2021008962 A MX2021008962 A MX 2021008962A MX 2021008962 A MX2021008962 A MX 2021008962A
Authority
MX
Mexico
Prior art keywords
osteoarthritis
symptoms
treating signs
signs
treating
Prior art date
Application number
MX2021008962A
Other languages
English (en)
Inventor
Christine Ruth West
Mark Thomas Brown
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021008962A publication Critical patent/MX2021008962A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/505—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of bone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)

Abstract

La presente invención se relaciona con el tratamiento de signos y síntomas de la osteoartritis con un anticuerpo del factor de crecimiento anti-nervioso (NGF).
MX2021008962A 2019-01-28 2020-01-27 Metodo para tratar signos y sintomas de la osteoartritis. MX2021008962A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962797537P 2019-01-28 2019-01-28
US201962835297P 2019-04-17 2019-04-17
US201962851988P 2019-05-23 2019-05-23
US201962923663P 2019-10-21 2019-10-21
US201962947113P 2019-12-12 2019-12-12
US201962949777P 2019-12-18 2019-12-18
PCT/IB2020/050611 WO2020157629A1 (en) 2019-01-28 2020-01-27 Method of treating signs and symptoms of osteoarthritis

Publications (1)

Publication Number Publication Date
MX2021008962A true MX2021008962A (es) 2021-08-24

Family

ID=69467599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008962A MX2021008962A (es) 2019-01-28 2020-01-27 Metodo para tratar signos y sintomas de la osteoartritis.

Country Status (11)

Country Link
US (1) US20220089710A1 (es)
EP (1) EP3917569A1 (es)
JP (1) JP2020117502A (es)
KR (1) KR20210121126A (es)
CN (1) CN113453717A (es)
AU (1) AU2020215162A1 (es)
BR (1) BR112021012452A2 (es)
CA (1) CA3127751A1 (es)
IL (1) IL285169A (es)
MX (1) MX2021008962A (es)
WO (1) WO2020157629A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022195504A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
KR20230088966A (ko) 2021-12-13 2023-06-20 서울대학교산학협력단 골관절염 예방 및 진행억제 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
MY153781A (en) 2007-08-10 2015-03-13 Regeneron Pharma High affinity human antibodies to human nerve growth factor
CN102159204B (zh) 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂

Also Published As

Publication number Publication date
IL285169A (en) 2021-09-30
KR20210121126A (ko) 2021-10-07
AU2020215162A1 (en) 2021-07-15
US20220089710A1 (en) 2022-03-24
JP2020117502A (ja) 2020-08-06
EP3917569A1 (en) 2021-12-08
WO2020157629A1 (en) 2020-08-06
CN113453717A (zh) 2021-09-28
BR112021012452A2 (pt) 2021-09-08
CA3127751A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
PH12019502283A1 (en) Anti-lag3 antibodies
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
PH12020552229A1 (en) Il-11ra antibodies
MX2019010922A (es) Anticuerpos anti-phf-tau y usos de estos.
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
PH12020551444A1 (en) Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
MX2022006992A (es) Metodos para tratar los trastornos relacionados con il-4/il-13 identificados digitalmente.
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
CY1123784T1 (el) Αντισωματα enanti-tnf αλφα και λειτουργικα θραυσματα αυτων
MX2021008962A (es) Metodo para tratar signos y sintomas de la osteoartritis.
PH12018500362A1 (en) An improved refolding process for antibodys fragments
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
PH12018501739A1 (en) Antibodies for il-17c
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
EA201890005A1 (ru) АКТИВАТОР С НИЗКИМ ЗНАЧЕНИЕМ pH ДЛЯ ВЕЩЕСТВ-ЗАМЕНИТЕЛЕЙ КЛИНКЕРА
PH12021550607A1 (en) Antibodies and methods for treatment of lyssavirus infection
EA202191173A1 (ru) Моноклональное антитело, которое специфически связывается с cd20
MX2021002653A (es) Uso de moduladores de cftr para el tratamiento de condiciones cerebrovasculares.
WO2019028012A3 (en) METHODS OF USING PEMBROLIZUMAB AND TREBANANIB